Categories: inhibitorsNew-Onset

New-Onset IBD and IL-17 Inhibitors: What Is the Risk?

Patients with inflammatory/autoimmune diseases who initiated treatment with interleukin (IL)-17 inhibitors did not have a higher risk for the development of inflammatory bowel disease (IBD), but only after taking into account the severity of their underlying disease, French investigators reported.

Although the risk of IBD was significantly higher among initiators of IL-17 inhibition compared with patients starting apremilast (Otezla), with a propensity-score weighted hazard ratio of 3.8 (95% CI 2.1-6.8), no difference was seen when patients starting IL-17 inhibitors were compared with etanercept (Enbrel) initiators, with a hazard ratio of 0.8 (95% CI 0.5-1.2, P=0.30), reported Christina Bergqvist, MD, of Henri Mondor Hospital in Créteil, France, and colleagues.

This difference may be explained by the patient differences in the treatment groups, with those starting an IL-17 inhibitor or etanercept more commonly having had previous exposure to biologic therapies. “Patients included in the IL-17 inhibitor or etanercept groups probably presented a more severe disease compared with patients on apremilast. Thus, they were at higher risk to develop an IBD,” the investigators wrote online in Arthritis & Rheumatology.

Epidemiologic studies have demonstrated clear associations between psoriasis, psoriatic arthritis, and ankylosing spondylitis and the subsequent development of IBD.

The IL-17 inhibitors secukinumab (Cosentyx), ixekizumab (Taltz), and brodalumab (Siliq) have been recognized as highly effective therapies for these conditions, with secukinumab and ixekizumab being approved for all three. (Brodalumab has only been approved in the U.S. for psoriasis.)

However, there have been reports of patients with psoriasis developing new-onset IBD after exposure to IL-17 inhibitors, and clinical trials evaluating these agents as potential treatments for IBD were stopped because of worse outcomes than with placebo. But little information is available about IBD risks among patients receiving IL-17 inhibitors in real-world settings.

To investigate this, the researchers analyzed data from the French national health data system for the years 2016 to 2019 for patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis treated with IL-17 inhibitors. The comparators chosen were apremilast, because it was approved for use in France during the same time period as the IL-17 inhibitors (to minimize selection bias), and etanercept, as other tumor necrosis factor inhibitors are themselves approved for use as treatment for IBD.

The primary endpoint was the development of either Crohn’s disease or ulcerative colitis, and the analysis was propensity score weighted.

The study included 16,793 new users of IL-17 inhibitors (mean age 48, median follow-up 323 days, 46% men), as well as 20,556 new users of apremilast (mean age 53, median follow-up 212 days, 53% men) and 10,294 new users of etanercept (mean age 46, median follow-up 276 days, 44% men).

Patients in the IL-17 inhibitor and etanercept groups were younger and more often women. Biologic use within the previous 2 years was reported by 71% of the IL-17 inhibitor group compared with only 7% of the apremilast group and 27% of the etanercept group. The IL-17 inhibitor and etanercept groups also more often used systemic steroids and methotrexate (55% and 35% for IL-17; 57% and 27% for etanercept) compared with t

Read More

News Bot

Share
Published by
News Bot

Recent Posts

Residents Say German Towns Got Little Warning Before Huge Floods

AHRWEILER, Germany (AP) — Like other residents of his town in Germany, Wolfgang Huste knew…

46 mins ago

U.S. Olympians Chant Jill Biden’s Name As First Lady Cheers On Swimmers In Tokyo

Members of the U.S. swimming team cheered and chanted from the stands for U.S. first…

46 mins ago

TV Network Admits It Covered Olympic Opening Ceremony In ‘Inappropriate’ Way

South Korean TV network MBC’s coverage of the Tokyo Olympics opening ceremony on Friday went…

46 mins ago

Plato Data and Blockleaders Partner to Leverage Plato’s W3 Blockchain Platform

Washington, D.C., July 23, 2021 - (ACN Newswire) - Plato Technologies Inc., the provider of…

46 mins ago

A Blockchain Art Show?

Thursday, 22 July 2021, 08:00 HKT/SGT    Source: GBA Washington, D.C., July 22, 2021 - (ACN Newswire)…

46 mins ago

Biles and Ledecky Headline Day 2 of Olympic Competition

TOKYO—Two of America’s star Olympians headline Sunday’s events at the Tokyo Games as Simone Biles…

46 mins ago